Integra LifeSciences Holdings Corporation (IART)
Integra LifeSciences Holdings Corporation (IART) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Mojdeh Poul - President, CEO & Director Lea Knight - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Good morning, everyone, and welcome to Day 3 of the Morgan Stanley Global Healthcare Conference. Thanks so much, everyone, for joining.
Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Executives Christopher Ward – Senior Director of Investor Relations Lea Daniels Knight – Executive VP & CFO Mojdeh Poul – President, CEO & Director Analysts Lilia-Celine Breton Lozada - JPMorgan Chase & Co, Research Division Ravi Misra - Truist Securities, Inc., Research Division Unknown Analyst Vikramjeet Singh Chopra - Wells Fargo Securities, LLC, Research Division Xuyang Li - Jefferies LLC, Research Division Operator Good day, and thank you for standing by. Welcome to the Integra LifeSciences Second Quarter 2025 Financial Results Call.
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
Integra enrolls first pediatric patient in AERA registry to evaluate real-world use of its ETBD system and expand ENT market presence.
Integra (IART) Up 2.3% Since Last Earnings Report: Can It Continue?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Is the Options Market Predicting a Spike in Integra LifeSciences Stock?
Investors need to pay close attention to Integra LifeSciences stock based on the movements in the options market lately.
Integra Q1 Earnings Miss Estimates, Stock Down, '25 EPS Outlook Cut
IART's first-quarter 2025 earnings lag the consensus mark. Q2 revenue projections are bleak.
Compared to Estimates, Integra (IART) Q1 Earnings: A Look at Key Metrics
The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Integra LifeSciences (IART) Q1 Earnings Miss Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.55 per share a year ago.
Is This the Right Time to Hold Integra Stock in Your Portfolio?
IART stays on investors' radar courtesy of its strong prospects in the CSS segment and international growth.
Integra LifeSciences: Light At The End Of The Tunnel, Or Another Oncoming Train? (Rating Upgrade)
Integra LifeSciences had a rough 2024 as the company's quality control remediation efforts had a bigger than expected negative impact on results. Q4 '24 offered some stability with organic revenue growth and improved adjusted gross margins. 2025 guidance looks cautious, and a big cut to Q1 '25 expectations suggests that management may be pulling forward some of the lingering remediation costs.
